	US 12,241,077 B2
	Adeno-associated virus (AAV) systems for treatment of genetic hearing loss
Christopher Bartolome, Billerica, MA (US); Luis David Jaramillo, Cambridge, MA (US); Adrian M. Timmers, Burlington, MA (US); Steven Pennock, Leominster, MA (US); and Mark Shearman, Alachua, FL (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Sep. 30, 2020, as Appl. No. 17/038,482.
Claims priority of provisional application 62/907,834, filed on Sep. 30, 2019.
Prior Publication US 2021/0095313 A1, Apr. 1, 2021
Int. Cl. C12N 15/85 (2006.01); C07H 21/04 (2006.01); C12N 15/66 (2006.01); C12N 15/86 (2006.01); C12N 15/864 (2006.01)

CPC C12N 15/86 (2013.01) [C07H 21/04 (2013.01); C12N 15/66 (2013.01); C12N 15/8645 (2013.01); C12N 2510/00 (2013.01); C12N 2710/10041 (2013.01)]

18 Claims

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a codon optimized gap junction protein beta 2 (GJB2), wherein the nucleic acid sequence is at least 85% identical to SEQ ID NO: 18.